Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics.

MLA

Tierling, Sascha, et al. “Bisulfite Profiling of the MGMT Promoter and Comparison with Routine Testing in Glioblastoma Diagnostics.” Clinical Epigenetics, vol. 14, no. 1, Feb. 2022, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s13148-022-01244-4.

APA

Tierling, S., Jürgens-Wemheuer, W. M., Leismann, A., Becker-Kettern, J., Scherer, M., Wrede, A., Breuskin, D., Urbschat, S., Sippl, C., Oertel, J., Schulz-Schaeffer, W. J., & Walter, J. (2022). Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics. Clinical Epigenetics, 14(1), 1–12. https://doi.org/10.1186/s13148-022-01244-4

Chicago

Tierling, Sascha, Wiebke M. Jürgens-Wemheuer, Alea Leismann, Julia Becker-Kettern, Michael Scherer, Arne Wrede, David Breuskin, et al. 2022. “Bisulfite Profiling of the MGMT Promoter and Comparison with Routine Testing in Glioblastoma Diagnostics.” Clinical Epigenetics 14 (1): 1–12. doi:10.1186/s13148-022-01244-4.